Healthcare / BiotechnologyNSE
$1150.00
+24.80 (+2.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-959.4M · quality 69.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$34.9B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-10.7%
↓Gross Margin
60.3%
↑Debt/Equity
0.39
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+56.7%
FCF CAGR
—
FCF margin
-36.6%
FCF / Net income
2.67x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $5.39B · net income $-739.4M · FCF $-1.97B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $5.39B | $5.39B | $2.93B | $1.80B | $1.40B |
| Net Income | $-739.4M | $-739.4M | $-564.0M | $-143.5M | $-57.7M |
| EBITDA | $199.8M | $199.8M | $-36.6M | $82.1M | $97.5M |
| EPS | — | — | -20.68 | -5.59 | -2.29 |
| Gross Margin | 60.3% | 60.3% | 53.1% | 44.5% | 39.4% |
| Operating Margin | -11.9% | -11.9% | -16.7% | -7.0% | -2.7% |
| Net Margin | -13.7% | -13.7% | -19.3% | -7.9% | -4.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.39 | 0.39 | 0.62 | 1.06 | 0.56 |
| Current Ratio | 1.93 | 1.93 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.97B | $-1.97B | $-959.4M | $-226.9M | $-145.1M |
| Returns | |||||
| ROE | -10.7% | -10.7% | -25.2% | -15.9% | -7.2% |
| Valuation | |||||
| EV/EBITDA | — | — | — | 173.85 | 78.28 |
| P/B | — | — | 9.94 | 14.81 | 8.94 |
| Growth & Yield | |||||
| Revenue Growth | 83.9% | 83.9% | 62.3% | 29.0% | — |
| EPS Growth | — | — | -269.9% | -144.1% | — |
| Dividend Yield | 0.1% | 0.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+15.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-20.68 → n/d
Residual
+15.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.